Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Akkermansia muciniphila EB-AMDK 27
- Development stage
- Preclinical
- Lead developer
- Enterobiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Akkermansia muciniphila EB-AMDK 27 is a next-generation probiotic bacterial strain developed by the South Korean company Enterobiome. Isolated from healthy human fecal samples, this specific strain (deposit number KCTC 13758BP) is a live bacterial therapeutic designed to treat metabolic and inflammatory diseases. Preclinical studies in high-fat diet-induced obese mice have demonstrated its ability to inhibit lipid accumulation, improve glucose homeostasis and insulin sensitivity, and restore gut barrier integrity. The strain functions as a mucin-degrading, anaerobic, Gram-negative bacterium that modulates the gut microbiota to suppress appetite and prevent body weight gain.
- Other names
- Akkermansia muciniphila strain EB-AMDK 27
02
Targets
MUC2 (Mucin-2)
Beyond the preview
Go deeper on Akkermansia muciniphila EB-AMDK 27.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akkermansia muciniphila EB-AMDK 27.